Emerging Insights in Mantle Cell Lymphoma From ASH 2025

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK inhibitor–refractory disease.

Michael Wang, MD, reviews ASH 2025 data showing durable safety with long-term BTK inhibition, promising next-generation targeted agents, sustained CAR T-cell efficacy, and evidence favoring upfront combination therapy over sequential treatment in mantle cell lymphoma.

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.

Michael Wang, MD, highlights standout translational studies from ASH 2025 that advance understanding of prognosis and drug resistance in mantle cell lymphoma through epigenetic profiling and the biology of drug-tolerant persister cells.

Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune therapies—paired with MRD monitoring and intensified maintenance strategies—is redefining outcomes in mantle cell lymphoma.